BPC-157: What the Studies Actually Show
Last updated: October 2026
BPC-157 is a 15-amino acid peptide studied mainly in animals for tissue repair, anti-inflammatory, and gut-healing effects. A 2025 systematic review screened 544 articles and included 36 studies (35 preclinical, 1 clinical). It remains a research compound without FDA approval, and no clinical safety data were found in that review.
Research Supplier
The research supplier we link to (affiliate link). We have not independently tested this product.
🧬 BPC-157 from Swiss Chems →On July 23–24, 2026 the FDA's Pharmacy Compounding Advisory Committee voted to recommend BPC-157 for the 503A compounding list. It is a non-binding recommendation, not FDA approval and not legal to compound yet, pending HHS action and formal rulemaking. Read the full vote breakdown →
A visual breakdown of 30+ years of research on the most talked-about healing peptide
Track your vials and inventory on paper
Printable vial and inventory sheets for your own research records. Every value is entered by you. Free to build and preview; $5/month to unlock printing.
Background
What Is BPC-157?
A naturally occurring peptide with a 30-year research history. Here's what it actually is, how it works, and how it's administered.
Origin
A 15-amino-acid peptide (pentadecapeptide) naturally found in human gastric juice. First described in 1993 by Dr. Predrag Sikiric. Full name: Body Protection Compound-157.
How It Works
Activates VEGFR2 and nitric oxide signaling (Akt-eNOS pathway). Modulates angiogenesis: promotes new blood vessel growth in injured tissue while inhibiting VEGF-driven MAPK signaling in tumor cell lines (Radeljak 2004). Reduces inflammatory cytokines, enhances growth hormone receptor expression, and activates ERK1/2 signaling for cell repair.
Pharmacology
Half-life: less than 30 minutes. Metabolized in liver. Cleared by kidneys. Routes studied: injection (subcutaneous, intramuscular, intraperitoneal, intraarticular), oral, and topical.
Mechanism of Action
Four Healing Pathways
BPC-157 works through more than one pathway. Researchers have identified at least four distinct biological mechanisms active across tissue types.
Angiogenesis (Blood Vessel Growth)
Enhances VEGFR2 activity and NO production. Creates new capillaries in damaged tissue. Particularly beneficial in poorly vascularized tissues like tendons, which heal slowly precisely because they have limited blood supply.
Anti-Inflammatory
Reduces pro-inflammatory cytokines. Upregulates cytoprotective factors including heme oxygenase-1 (HO-1). Reduces oxidative stress and prevents mitochondrial dysfunction — protecting cells from secondary damage during healing.
Neuromuscular Protection
Stabilizes acetylcholine receptors at the neuromuscular junction. Reverses paralysis from neuromuscular blockers in animal models. Restores glutamatergic signaling, a pathway relevant to both peripheral nerve function and CNS recovery.
Tissue Repair (ERK1/2)
Activates ERK1/2 signaling pathway. Enhances endothelial cell proliferation and migration. Promotes collagen formation and extracellular matrix development: the structural scaffolding required for functional tissue regeneration.
Preclinical Evidence
What Healed in Animal Studies
BPC-157 showed positive results across many musculoskeletal injuries in animal models. Bar size represents number of positive studies per tissue type.
ALL data below is preclinical (animal research). These results come from studies in rats, mice, and rabbits, not humans. Animal results do not automatically translate to human outcomes. This data demonstrates biological plausibility and guides further research, not clinical effectiveness in people.
Human Evidence
The Elephant in the Room: Human Evidence
Thirty years of animal research. Three small pilot studies in humans. Here's what we actually know about BPC-157 in people.
Intraarticular injection for chronic knee pain. 7 of 12 patients (58%) reported pain relief lasting >6 months after a single injection. Retrospective design: no control group, limited conclusions.
Small pilot study examining BPC-157 for bladder inflammation. Extremely limited sample size, early-stage exploratory research only.
Safety and dosing study examining intravenous administration. No adverse effects reported. Primarily established initial safety signals, not efficacy data.
BPC-157 research began in 1993. A 2025 systematic review screened 544 articles from 1993–2024 and included 36 studies, 35 of them preclinical. The review found no randomized controlled trials in humans (papers from 2003 and 2011 mention IBD clinical trials as PL 14736, but no results appear in the reviews cited here). This is an extraordinary gap between preclinical promise and clinical validation. The peptide may work exactly as claimed, or animal results may not translate. We do not know.
Origins of Research
The Gut Connection: Where BPC-157 Started
BPC-157 was originally isolated from gastric juice and first studied for gastrointestinal healing. This remains its most evidence-backed application area.
Counteracted diclofenac (NSAID)-induced stomach, intestinal, and liver lesions in rats (PMID 21295044). Human data are lacking.
Healed cysteamine-induced colitis. Promoted intestinal anastomosis healing. Described in 2003 and 2011 papers as in IBD clinical trials as PL-14736 (Pliva, Croatia); no trial results appear in the reviews cited here.
Healed colocutaneous fistulas via nitric oxide system modulation. Fistulas are notoriously difficult to treat, which makes this a potentially high-value application.
Reversed short bowel syndrome in animal models. Enhanced intestinal adaptation and mucosal regrowth following extensive bowel resection.
Enhanced mucosal integrity and barrier function. Reduced intestinal permeability in animal models, though "leaky gut" remains a contested clinical concept.
Legal & Regulatory
The Regulatory Landscape
BPC-157's status varies dramatically by context: from research chemical to explicitly banned substance. Know where you stand.
| Organization | Status | Year |
|---|---|---|
| FDA | ⚠ Category 2 (withdrawn) Bulk drug substance: safety concerns; FDA's current list shows the nomination withdrawn | 2023 |
| WADA | ✕ Banned Specifically named on prohibited list | 2022 |
| UFC | ✕ Banned Specifically banned | 2022 |
| NFL | ✕ Banned Specifically banned | 2022 |
| NBA | ◆ Covered Non-specific PED ban covers peptide hormones | — |
| NHL | ◆ Covered Non-specific PED ban | 2013 |
| MLB | ◆ Covered Peptide hormone ban | 2019 |
| NCAA | ◆ Covered Peptide hormone ban | 1999 |
Breaking Research (2024-2025)
New Clinical Data: First Human Studies
Published human results are limited to small pilots from 2021 to 2025 (earlier IBD trials as PL 14736 are mentioned in older papers, without results in the reviews cited here). Here's what they reported.
2025 IV Safety Pilot
Two healthy adults received IV infusions of 10 mg and then 20 mg (the first published study of intravenous BPC-157 in humans). Results: well tolerated, no side effects reported, and no measurable effects on tested heart, liver, kidney, thyroid, or blood glucose biomarkers. Lee & Burgess, Altern Ther Health Med, 2025 — PMID 40131143
2025 HSS Journal Systematic Review
This systematic review in HSS Journal (Hospital for Special Surgery) screened 544 articles spanning 1993-2024, including 36 studies (35 preclinical, 1 clinical). Conclusion: based on level IV and V studies, BPC-157 "shows promise for promoting recovery from musculoskeletal injuries." Preclinical safety studies showed no adverse effects across several organ systems, but no clinical safety data were found. The review also reports a half-life of less than 30 minutes. Vasireddi et al., HSS J, 2025 — PMID 40756949
2024 Bladder Wall Injection Study
A pilot study examined 12 women with moderate to severe interstitial cystitis who received 10mg BPC-157 injected directly into the bladder wall. It is one of the first targeted human applications beyond musculoskeletal tissue. Lee, Altern Ther Health Med, 2024 — PMID 39325560
2021 Knee Pain Retrospective
In a retrospective chart review of 17 patients with multiple types of knee pain, 16 were surveyed by phone; of the 12 who received intraarticular BPC-157 alone, 11 (91.6%) reported significant pain improvement. The 2025 HSS systematic review summarizes this study as 7 of 12 patients reporting relief lasting more than 6 months. Small sample, retrospective phone survey, no control group. Lee & Padgett, Altern Ther Health Med, 2021 — PMID 34324435
Alcohol-Induced Organ Damage (Preclinical)
In rats given alcohol chronically, the Sikirić group reported that BPC-157 both prevented and reversed portal hypertension and the associated liver lesions (outperforming ranitidine and matching propranolol in that model). A separate intragastric-alcohol study found BPC-157 counteracted acute gastric lesions framed as a broader peripheral-and-central injury syndrome. Important caveat: these are animal models only — there are no human trials of BPC-157 for alcohol-related liver or organ damage, and none of this implies it is safe to drink. Prkačin et al., J Physiol Paris, 2001; Gojković et al., Biomedicines, 2021 — PMID 11595456, PMID 34680419
2025 ACG Review (Oral BPC-157): A systematic-review abstract presented at the American College of Gastroenterology 2025 Annual Meeting (published in The American Journal of Gastroenterology supplement) described oral BPC-157 as "an emerging adjunct to gastrointestinal therapies." Preclinical findings: protective against NSAID-induced injury, improved outcomes in IBD/ulcer/fistula models, and modulation of growth-hormone-receptor and angiogenic pathways. The abstract noted that human trials are needed. This appeared in a mainstream GI venue, not a niche peptide publication. (ACG 2025 meeting abstract S808 — source)
Animal Toxicology Summary: In a 2020 preclinical safety study in mice, rats, rabbits, and dogs, BPC-157 was well tolerated and caused no serious toxicity. Repeated dosing in dogs produced a decrease in creatinine at 2 mg/kg that resolved after 2 weeks off; local injection irritation was mild, and no genetic or embryo-fetal toxicity was found. Xu et al., “Preclinical safety evaluation of body protective compound-157”, Regul Toxicol Pharmacol, 2020 — PMID 32334036
Protocol Data
Common Protocol: BPC-157 + TB-500 Stack
The healing peptide stack most commonly discussed in the research community. Different mechanisms, complementary timing.
Why the combination? BPC-157 has a reported half-life of less than 30 minutes (2025 HSS systematic review). TB-500 is described as acting more systemically. The stack targets different healing pathways: BPC-157 for localized tissue repair and gut healing, TB-500 for systemic inflammation and deeper tissue regeneration.
No human dose for BPC-157 or TB-500 has been established in a trial. The only published human dosing is from small pilots (for example, the 2-person IV safety pilot above). Community loading and maintenance schedules are not reproduced here.
Cost Estimate
Prices vary by supplier. Quality and purity vary significantly between sources.
Expected Timeline
No controlled human study has established a timeline for BPC-157 effects. Week-by-week improvement timelines found online are anecdotal reports, not trial findings.
Oral BPC-157 for Gut Health: No human oral dose has been established in a trial. The peptide is uniquely stable in gastric acid, unlike most peptides that are destroyed by digestive enzymes.
Safety Data
Safety: What We Know and Don't Know
A tale of two datasets: a preclinical record without serious toxicity, and a large gap in human safety data.
- No adverse effects across several organ systems in preclinical studies
- No LD50 established: researchers couldn't find a lethal dose in animal models
- No genetic or embryo-fetal toxicity was found in a 2020 animal safety study (PMID 32334036); carcinogenicity was not reported
- Stable in gastric juice (unlike most peptides, which are rapidly degraded)
- Originally isolated from human gastric juice; the research compound is synthetic
- No clinical safety data from rigorous, controlled trials in humans
- Only 3 small pilot studies in humans have been published: insufficient to establish a safety profile (papers from 2003 and 2011 mention IBD clinical trials as PL 14736, but no results appear in the reviews cited here)
- No long-term safety data at any dose in any population
- Unregulated manufacturing creates real contamination and dosing accuracy risks
- Quality varies wildly between research chemical suppliers; purity not guaranteed
- FDA placed it in Category 2 (safety concerns) in 2023; nomination since withdrawn per FDA's current list (regulatory red flag)
Community reports (anecdotal): A recurring theme among long-term users is that BPC-157 is "the quiet one": the benefit is subtle enough that they only realize it was working once they run out and old aches or gut issues return. It's an interesting pattern, but it's also exactly the kind of report most vulnerable to placebo and recall bias. Read it as an early signal from self-reported experience, not evidence; the controlled human data that would confirm it doesn't exist yet.
Self-Assessment
Who Researches BPC-157?
This Research Is Commonly Explored By People Who...
- Are dealing with chronic tendon, ligament, or soft tissue injuries and want to understand the preclinical evidence
- Are interested in gastric pentadecapeptide research and its mechanisms in tissue repair
- Want to understand what animal studies show about gut healing and the gut-brain axis
- Are exploring options beyond traditional rehab for persistent musculoskeletal issues
- Want an honest assessment of where BPC-157 research stands (mostly preclinical, limited human data)
This Research May Not Be Relevant If...
- You expect FDA-approved clinical data: BPC-157 lacks large-scale human trials
- You have an acute injury that needs immediate medical attention: see a doctor first
- You're looking for a replacement for physical therapy or surgery: BPC-157 is studied as a complement, not a substitute
Want the Complete Protocol Guide?
Dosing schedules, interaction warnings, and cycle protocols for 20+ compounds, all in one place.
Get the Guide: $19 (normally $29) →
The Peptide Buyer’s Playbook ($19)
Bottom Line
What the Research Actually Tells Us
Separating what the peer-reviewed evidence confirms from what we don't know yet.
- BPC-157 has a large body of preclinical research, rated level IV/V evidence by a 2025 systematic review
- Multiple mechanisms of action suggested by preclinical studies: angiogenesis, anti-inflammatory, ERK1/2 signaling, nitric oxide system
- Consistent positive results across muscle, tendon, ligament, bone, nerve, and gut models in animals
- Animal safety studies found no serious toxicity (a reversible creatinine decrease in dogs at 2 mg/kg and mild injection-site irritation were reported)
- Derived from a protein in human gastric juice; the version studied and sold is a synthetic peptide
- Almost no human clinical trial data: just 3 tiny pilot studies across 30+ years of research
- Long-term effects in humans are completely unknown at any dose
- Optimal human dosing not established by rigorous clinical trials
- Unregulated products may contain contaminants or incorrect doses (real risk)
- FDA placed it in Category 2 (safety concerns) in 2023, restricting pharmacy compounding; FDA's current list shows that Category 2 nomination as withdrawn
- Banned in virtually all major competitive sports leagues worldwide
Read the Numbers Carefully
One Lab Produced Most of the Evidence
"544 articles" sounds overwhelming. But where that research comes from matters as much as how much of it there is, and it's the caveat most BPC-157 pages leave out.
🔬 The volume is real, but it isn't independent
A PubMed author search (June 2026) reveals the story behind the headline number: of roughly 219 indexed "BPC 157" papers, about 173 (close to four in five) list Dr. Predrag Sikiric of the University of Zagreb, Croatia, as an author. BPC-157 was first described by his lab in 1993, and his group has driven the field ever since.
That doesn't make the findings wrong, but a deep body of work concentrated in one research group is not the same as a result many independent labs have reproduced. In evidence terms, breadth of replication counts as much as raw study volume, and independent corroboration outside that group remains comparatively thin.
⚖️ A conflict-of-interest note, for balance, not accusation
Dr. Sikiric is the named inventor on the original BPC patent (US 5,288,708, filed 1989, now expired) and is listed as CEO of Diagen d.o.o., a company that markets a "stable" version of BPC-157. A February 2026 STAT News / Undark investigation additionally reported a tie to PharmaCotherapia (a company that sponsored a BPC-157 clinical trial) and noted those interests were not disclosed in the papers its reporters reviewed.
None of this means the research is fraudulent. It is simply a reason to weight independent replication and genuine human trials heavily, and to treat single-group, commercially-adjacent preclinical results with appropriate caution.
Sources: PubMed author search (Sikiric P[au] AND BPC 157), observed June 2026; US Patent 5,288,708A (Google Patents); Diagen d.o.o. (bpc157.si); STAT News / Undark, Feb 3 2026. Separately (independent of the authorship point above), the two 2025 reviews cited elsewhere on this page (the narrative review “Regeneration or Risk?” on BPC-157 for musculoskeletal healing, PMID 40789979, 40756949) confirm the human evidence base remains limited to a few small pilot studies.
Critical Insight
Opposite Vessel Effects in Different Tissue Models
Separate animal studies report opposite effects on blood vessel growth in different tissues. No study has tested whether this reflects a tissue-specific response.
🧬 Why This Matters
Separate studies report BPC-157 promoting blood-vessel growth in injured tissue and inhibiting VEGF-driven signaling in tumor cell lines. Whether this reflects true tissue-specific regulation has not been tested directly.
Preclinical data (animal models). No human randomized controlled trials.
2026 Update
Verified Study Citations
Four key studies frequently cited in the BPC-157 community, with verified PubMed IDs and key findings.
Corneal Injury: Perforating Wound Healing
Perforating corneal injury in rat and pentadecapeptide BPC 157
Spinal Cord Injury: Motor Function Recovery
Stable gastric pentadecapeptide BPC 157 can improve the healing course of spinal cord injury and lead to functional recovery in rats
NSAID Toxicity: Multi-Organ Protection
Pentadecapeptide BPC 157 and its effects on a NSAID toxicity model: diclofenac-induced gastrointestinal, liver, and encephalopathy lesions
Achilles Tendon: Accelerated Healing
Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth
All preclinical data from rat models. No human randomized controlled trials have been conducted for these specific applications.
Source Material
Study Details & Citations
Data on this page comes from published systematic reviews, primary studies, and other sources cited inline. Full citations below.
Primary Source: Systematic Review: Orthopaedic Sports Medicine
Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review
Secondary Source: Narrative Review: Musculoskeletal Healing
Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing
Continue Reading
Related Resources
Dosing guides, delivery methods, and safety information for BPC-157 and related peptides.
Research Supplier
The research supplier we link to (affiliate link). We have not independently tested this product.
Affiliate links support HighPeptides at no extra cost. Swiss Chems publishes third-party HPLC COAs for selected products (vendor-published, a claim to verify).
Essential Supplies
Everything you need for peptide preparation and administration
Affiliate links support HighPeptides at no extra cost.
What to Expect: A Healing Timeline
Based on animal model research (30+ years; 36 studies included in a 2025 systematic review) and the known biological mechanisms of BPC-157. No controlled human trials have been completed. These phases summarize preclinical findings and are not a human timeline.
Initial Healing Cascade & Inflammation Reduction
In animal studies, BPC-157 is reported to act on VEGF and nitric oxide (NO) signaling (Sikiric et al.). This triggers angiogenesis (new blood vessel formation) in damaged tissue. Reduced inflammatory cytokines are reported in animal models; human effects have not been measured in controlled trials.
Tissue Repair Acceleration & Pain Reduction
Animal studies report fibroblast and collagen formation in injured tendons. The new blood vessels formed through VEGF upregulation begin supplying oxygen and nutrients to previously hypovascular tissue (tendons heal slowly in part because of limited blood supply). In a rat Achilles tendon transection study (Staresinic et al., 2003), BPC-157 improved functional, biomechanical, and microscopic healing compared with controls over 14 days.
Significant Structural Healing
In animal models, BPC-157 improved functional, structural, and biomechanical outcomes in muscle, tendon, ligament, and bone injuries (2025 HSS systematic review); no controlled human study has measured a 3-month outcome. Studies also demonstrate significant recovery of crush-injured muscle (Novinscak et al.), nerve repair (Gjurasin et al., 2010), and gut lining restoration in models of IBD and NSAID-induced damage.
Long-Term Recovery & Tissue Remodeling
Extended animal studies suggest ongoing tissue remodeling and structural improvement beyond the acute healing phase. Long-term organ protection effects (gastric, hepatic, cardiac) have been documented in chronic stress and toxin exposure models. Important caveat: No long-term human trial data exists. The 2025 HSS Journal systematic review (PMC12313605) concludes only that level IV and V studies suggest BPC-157 shows promise, and found no clinical safety data; long-term human safety and efficacy remain unconfirmed.
Research-Grade BPC-157
Research-grade BPC-157 with COA. The peptide most cited for tendon, gut, and joint research.
Browse BPC-157 at Swiss Chems →Affiliate links support HighPeptides at no extra cost.
Disclaimer: This page is for educational and informational purposes only. It is not medical advice. BPC-157 is not approved by the FDA for any medical use. The FDA placed it in Category 2 of its bulk drug substances list in 2023; FDA's current list shows that Category 2 nomination as withdrawn. Always consult with a qualified healthcare provider before starting any supplement or peptide protocol. Data sourced from published peer-reviewed reviews (HSS Journal 2025, PMID 40756949 / PMC12313605; Current Reviews in Musculoskeletal Medicine 2025, PMID 40789979 / PMC12446177) and human pilot studies (PMID 40131143, 39325560, 34324435).
Who Is This For? What the Research Covers
What the Research Covers
- • Tendon, ligament, muscle, and bone injury: animal models
- • Gut lining and NSAID-induced damage: animal models
- • Knee pain, interstitial cystitis, IV safety: three small human pilots
- • No clinical safety data were found in the 2025 systematic review: this is not an established treatment for anyone
Not Ideal If You...
- • Are pregnant or breastfeeding: no safety data exists
- • Have active cancer or a history of cancer: BPC-157 promotes blood-vessel growth in animal models, cancer-related data are limited, and no human safety data exist (safety overview)
- • Are looking for a weight loss or muscle-building compound: BPC-157 is a healing peptide, not anabolic
- • Have no injury or gut issue to address: this isn't a general wellness supplement
⚕️ Always consult a healthcare provider before starting any peptide protocol.
Frequently Asked Questions
What is BPC-157?
BPC-157 (Body Protection Compound 157) is a synthetic pentadecapeptide consisting of 15 amino acids, derived from a protective protein found in human gastric juice. It is a research compound with extensive animal study data showing tissue repair, anti-inflammatory, and gut-healing properties. It is not FDA-approved and is currently classified as a research chemical in the United States.
Is BPC-157 safe?
Preclinical safety studies in animals have not shown serious toxicity. A 2025 systematic review found no clinical safety data, and a 2025 narrative review says its use should be approached with caution until well-designed trials are done. The human safety profile is unknown, it is not FDA-approved, and quality and purity vary between sources.
What does BPC-157 do?
BPC-157 has demonstrated multiple mechanisms of action in preclinical research: it accelerates healing of tendons, ligaments, muscles, and gut tissue; reduces inflammation via nitric oxide pathway modulation; promotes angiogenesis (new blood vessel formation); and protects the gastric lining. Animal studies show benefits for gut inflammation (IBD, leaky gut), sports injuries, and neurological function. Human data remains limited to case reports and small studies.
How do you take BPC-157?
BPC-157 can be administered subcutaneously (under the skin), intramuscularly, or orally. For gut-specific applications, oral administration (encapsulated or dissolved in water) has shown efficacy in animal models. There is no established human dosing protocol — all usage is off-label and for research purposes only.
Is BPC-157 legal?
In the United States, BPC-157 exists in a regulatory grey area. It is not FDA-approved as a drug and is not a controlled substance, but in 2023 the FDA placed it on its Category 2 list of bulk substances that compounding pharmacies cannot legally compound for human use; FDA's current list shows that Category 2 nomination as withdrawn. (At its July 23–24, 2026 meeting, an FDA advisory committee voted to recommend adding it to the 503A bulks list; that recommendation does not change its status until FDA completes rulemaking.) It can legally be purchased as a research chemical for non-human use. In most other countries it is similarly unscheduled but not approved for human use. Legal status varies by country.
Why does so much BPC-157 research come from one lab?
BPC-157 was discovered in 1993 by Dr. Predrag Sikiric's group at the University of Zagreb, Croatia, and a PubMed author search (June 2026) shows about 173 of the ~219 indexed BPC-157 papers — roughly four in five — still list him as an author. That heavy concentration matters: a large study count from a single research group is not the same as a finding many independent labs have reproduced. Sikiric also holds the original (now-expired) BPC patent and is CEO of a company marketing a "stable" BPC-157, and a 2026 STAT News/Undark investigation reported additional commercial ties that were not disclosed in the papers it reviewed. This doesn't make the research wrong, but it's a reason to weight independent replication and human clinical trials heavily and to read the preclinical results with appropriate caution.
Related Resources
Get the Free 2026 Peptide Protocol Stack
Twelve compounds across four pillars: metabolic, tissue repair, longevity, cognitive. Citations included, formatted to print. Sent straight to your inbox.